Edwards Lifesciences is a medical devices business based in the US. Edwards Lifesciences shares (EW) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $75.04 – a decrease of 0.19% over the previous week. Edwards Lifesciences employs 15,800 staff and has a trailing 12-month revenue of around $5.5 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $75.04 |
|---|---|
| 52-week range | $58.93 - $95.25 |
| 50-day moving average | $71.33 |
| 200-day moving average | $70.74 |
| Wall St. target price | $80.28 |
| PE ratio | 31.7395 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $2.38 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $74.92 from 2025-05-06
| 1 week (2025-04-30) | -0.76% |
|---|---|
| 1 month (2025-04-08) | 11.70% |
| 3 months (2025-02-07) | 6.50% |
| 6 months (2024-11-08) | 13.12% |
| 1 year (2024-05-08) | -11.95% |
|---|---|
| 2 years (2023-05-05) | -15.57% |
| 3 years (2022-05-06) | 100.52 |
| 5 years (2020-05-07) | 3.08% |
Valuing Edwards Lifesciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edwards Lifesciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Edwards Lifesciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, Edwards Lifesciences shares trade at around 32x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Edwards Lifesciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.2534. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Edwards Lifesciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Edwards Lifesciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.7 billion.
The EBITDA is a measure of a Edwards Lifesciences's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $5.5 billion |
|---|---|
| Operating margin TTM | 29.02% |
| Gross profit TTM | $4.4 billion |
| Return on assets TTM | 8.26% |
| Return on equity TTM | 16.64% |
| Profit margin | 75.71% |
| Book value | $16.99 |
| Market Capitalization | $44.2 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Edwards Lifesciences.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 21.68
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Edwards Lifesciences's overall score of 21.68 (as at 12/31/2018) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Edwards Lifesciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.78/100
Edwards Lifesciences's environmental score of 4.78 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 13.43/100
Edwards Lifesciences's social score of 13.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 10.96/100
Edwards Lifesciences's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Edwards Lifesciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Edwards Lifesciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Edwards Lifesciences has, for the most part, managed to keep its nose clean.
Edwards Lifesciences Corp was last rated for ESG on: 2019-01-01.
| Total ESG score | 21.68 |
|---|---|
| Total ESG percentile | 24.1 |
| Environmental score | 4.78 |
| Environmental score percentile | 6 |
| Social score | 13.43 |
| Social score percentile | 6 |
| Governance score | 10.96 |
| Governance score percentile | 6 |
| Level of controversy | 2 |
We're not expecting Edwards Lifesciences to pay a dividend over the next 12 months.
Edwards Lifesciences's shares were split on a 3:1 basis on 31 May 2020 . So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Edwards Lifesciences shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Edwards Lifesciences shares which in turn could have impacted Edwards Lifesciences's share price.
Over the last 12 months, Edwards Lifesciences's shares have ranged in value from as little as $58.93 up to $95.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Edwards Lifesciences's is 1.149. This would suggest that Edwards Lifesciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .